[
  {
    "ts": null,
    "headline": "Regeneron’s Blockbuster Dupixent Faces a New Rival",
    "summary": "The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.",
    "url": "https://finnhub.io/api/news?id=72ab8a0ed65ba42ffcf3d1414cbeeb86240470ea9c437ed7c9a9602e5fd18121",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752003060,
      "headline": "Regeneron’s Blockbuster Dupixent Faces a New Rival",
      "id": 135821933,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.",
      "url": "https://finnhub.io/api/news?id=72ab8a0ed65ba42ffcf3d1414cbeeb86240470ea9c437ed7c9a9602e5fd18121"
    }
  },
  {
    "ts": null,
    "headline": "Trump Says He’ll Set 50% Copper Tariff, Wait Year on Drug Levies",
    "summary": "(Bloomberg) -- President Donald Trump said he planned to implement a 50% duty on copper imports as part of a set of looming sectoral tariffs, while also indicating he could offer pharmaceutical manufacturers at least a year before applying a crippling 200% tariff on their foreign-made products.Most Read from BloombergAre Tourists Ruining Europe? How Locals Are Pushing BackCan Americans Just Stop Building New Highways?Denver City Hall Takes a Page From NASAPhiladelphia Trash Piles Up as Garbage W",
    "url": "https://finnhub.io/api/news?id=1fccd845f4c89020e26d492afff3027881ba9c88390597dc1d1652f6a7556f03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751998713,
      "headline": "Trump Says He’ll Set 50% Copper Tariff, Wait Year on Drug Levies",
      "id": 135818910,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- President Donald Trump said he planned to implement a 50% duty on copper imports as part of a set of looming sectoral tariffs, while also indicating he could offer pharmaceutical manufacturers at least a year before applying a crippling 200% tariff on their foreign-made products.Most Read from BloombergAre Tourists Ruining Europe? How Locals Are Pushing BackCan Americans Just Stop Building New Highways?Denver City Hall Takes a Page From NASAPhiladelphia Trash Piles Up as Garbage W",
      "url": "https://finnhub.io/api/news?id=1fccd845f4c89020e26d492afff3027881ba9c88390597dc1d1652f6a7556f03"
    }
  },
  {
    "ts": null,
    "headline": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
    "summary": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
    "url": "https://finnhub.io/api/news?id=3077807c43b78e2edb81b8f062b911184ce713eb3b6e888f3ad03d1dd34750d6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751981508,
      "headline": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
      "id": 135854926,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
      "url": "https://finnhub.io/api/news?id=3077807c43b78e2edb81b8f062b911184ce713eb3b6e888f3ad03d1dd34750d6"
    }
  },
  {
    "ts": null,
    "headline": "How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?",
    "summary": "ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.",
    "url": "https://finnhub.io/api/news?id=a18c12cd77ddee6772eeda08f133bcb8c233bd69bdcc839a042f8df8b92a629b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751977620,
      "headline": "How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?",
      "id": 135805660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.",
      "url": "https://finnhub.io/api/news?id=a18c12cd77ddee6772eeda08f133bcb8c233bd69bdcc839a042f8df8b92a629b"
    }
  },
  {
    "ts": null,
    "headline": "Schizophrenia Market Research and Forecast Report 2025-2034 | Emerging Therapies and Genetic Research Drive Growth with Bristol Myers Squibb, AstraZeneca, and Eli Lilly Leading",
    "summary": "The schizophrenia market is projected to grow from USD 7.78 billion in 2024 to USD 13.67 billion by 2034, with a CAGR of 5.80%. Key growth drivers include rising schizophrenia prevalence, increased use of long-acting injectable antipsychotics, and advances in genetic and digital therapeutics. The U.S. leads in market share due to its robust healthcare system. Schizophrenia Market Schizophrenia Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The \"Schizophrenia Market Report and Forecast 2025-203",
    "url": "https://finnhub.io/api/news?id=c10c9f7ec1a928a4f3710c0f4cce26ca1b02faf7c2e177ae419202b4780a48d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751975340,
      "headline": "Schizophrenia Market Research and Forecast Report 2025-2034 | Emerging Therapies and Genetic Research Drive Growth with Bristol Myers Squibb, AstraZeneca, and Eli Lilly Leading",
      "id": 135805005,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The schizophrenia market is projected to grow from USD 7.78 billion in 2024 to USD 13.67 billion by 2034, with a CAGR of 5.80%. Key growth drivers include rising schizophrenia prevalence, increased use of long-acting injectable antipsychotics, and advances in genetic and digital therapeutics. The U.S. leads in market share due to its robust healthcare system. Schizophrenia Market Schizophrenia Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The \"Schizophrenia Market Report and Forecast 2025-203",
      "url": "https://finnhub.io/api/news?id=c10c9f7ec1a928a4f3710c0f4cce26ca1b02faf7c2e177ae419202b4780a48d7"
    }
  },
  {
    "ts": null,
    "headline": "Anti-Obesity Drugs Market Research and Forecast Report 2025 | Market to Surpass $120 Billion by 2034 - Increased Strategic Merger and Initiatives to Meet Rising Demand",
    "summary": "The anti-obesity drugs market, valued at USD 3.20 billion in 2024, is propelled by rising obesity prevalence worldwide, aiming for USD 120.32 billion by 2034 at 43.72% CAGR. Key drivers include FDA-approved drugs like Liraglutide, strategic mergers, regulatory support, and rising awareness. Top players include Novo Nordisk and Eli Lilly. Anti-Obesity Drugs Market Anti-Obesity Drugs Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The \"Anti-Obesity Drugs Market Report and Forecast 2025-2034\" repo",
    "url": "https://finnhub.io/api/news?id=e576740d0bcefab4c39ab49aa6f5cbaf1a3db98c807dd4d1a8f49d4a9b5fdb1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751974740,
      "headline": "Anti-Obesity Drugs Market Research and Forecast Report 2025 | Market to Surpass $120 Billion by 2034 - Increased Strategic Merger and Initiatives to Meet Rising Demand",
      "id": 135805030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The anti-obesity drugs market, valued at USD 3.20 billion in 2024, is propelled by rising obesity prevalence worldwide, aiming for USD 120.32 billion by 2034 at 43.72% CAGR. Key drivers include FDA-approved drugs like Liraglutide, strategic mergers, regulatory support, and rising awareness. Top players include Novo Nordisk and Eli Lilly. Anti-Obesity Drugs Market Anti-Obesity Drugs Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The \"Anti-Obesity Drugs Market Report and Forecast 2025-2034\" repo",
      "url": "https://finnhub.io/api/news?id=e576740d0bcefab4c39ab49aa6f5cbaf1a3db98c807dd4d1a8f49d4a9b5fdb1d"
    }
  },
  {
    "ts": null,
    "headline": "Analysis: 'Trump Effect' website takes credit for US investment made under Biden",
    "summary": "Since then, Trump has said the investments have swelled to $14 trillion, or roughly half of the nation's annual gross domestic product.  The White House calls it \"The Trump Effect\" and features a rolling list on its website of more than 70 projects it says Trump's economic policies spurred, from a new bakery plant in Texas to a LEGO facility in Virginia and a microchip plant in Arizona.",
    "url": "https://finnhub.io/api/news?id=92e2dc58d493ce2276eb1aaea4aa576578a366cd8c115d7728a13b84fa6525b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751969010,
      "headline": "Analysis: 'Trump Effect' website takes credit for US investment made under Biden",
      "id": 135804198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Since then, Trump has said the investments have swelled to $14 trillion, or roughly half of the nation's annual gross domestic product.  The White House calls it \"The Trump Effect\" and features a rolling list on its website of more than 70 projects it says Trump's economic policies spurred, from a new bakery plant in Texas to a LEGO facility in Virginia and a microchip plant in Arizona.",
      "url": "https://finnhub.io/api/news?id=92e2dc58d493ce2276eb1aaea4aa576578a366cd8c115d7728a13b84fa6525b0"
    }
  },
  {
    "ts": null,
    "headline": "3 Underrated Dividend Growth Stocks to Buy and Hold for Years",
    "summary": "The stocks listed here each increased their dividend payments by more than 10% recently.  When you think of a great dividend stock to own, you're probably thinking of one that yields a high rate of return.  It can lead you down a path where you buy a stock with a risky payout, and you could overlook promising dividend stocks simply because their yields don't look all that high right now.",
    "url": "https://finnhub.io/api/news?id=2008312a67d7cfb3ff57e858abe45b7d76f49e65caef7807623b285daa1332c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751964900,
      "headline": "3 Underrated Dividend Growth Stocks to Buy and Hold for Years",
      "id": 135805032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stocks listed here each increased their dividend payments by more than 10% recently.  When you think of a great dividend stock to own, you're probably thinking of one that yields a high rate of return.  It can lead you down a path where you buy a stock with a risky payout, and you could overlook promising dividend stocks simply because their yields don't look all that high right now.",
      "url": "https://finnhub.io/api/news?id=2008312a67d7cfb3ff57e858abe45b7d76f49e65caef7807623b285daa1332c7"
    }
  },
  {
    "ts": null,
    "headline": "WeightWatchers names new medical chief, plans to offer menopause therapy and support",
    "summary": "NEW YORK (Reuters) -WeightWatchers on Tuesday named Dr. Kim Boyd as chief medical officer and said it was planning a new program to help women manage the transition into menopause and beyond, as part of its growth strategy in emerging from bankruptcy.  Boyd, a Stanford University graduate who has worked with several consumer health startups, said in an interview WeightWatchers is building upon its decades-long work providing weight management tools to also address the specific needs of people using obesity treatments.  WeightWatchers CEO Tara Comonte said such support for members using weight-loss drugs should appeal to health insurers and employers who pay for health benefits as they seek more sustainable management of the costly medications.",
    "url": "https://finnhub.io/api/news?id=f201236b591571b424a6c00d35d20a3ee38c63a4d30473e51a9e2b744a04ae4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751948367,
      "headline": "WeightWatchers names new medical chief, plans to offer menopause therapy and support",
      "id": 135804054,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NEW YORK (Reuters) -WeightWatchers on Tuesday named Dr. Kim Boyd as chief medical officer and said it was planning a new program to help women manage the transition into menopause and beyond, as part of its growth strategy in emerging from bankruptcy.  Boyd, a Stanford University graduate who has worked with several consumer health startups, said in an interview WeightWatchers is building upon its decades-long work providing weight management tools to also address the specific needs of people using obesity treatments.  WeightWatchers CEO Tara Comonte said such support for members using weight-loss drugs should appeal to health insurers and employers who pay for health benefits as they seek more sustainable management of the costly medications.",
      "url": "https://finnhub.io/api/news?id=f201236b591571b424a6c00d35d20a3ee38c63a4d30473e51a9e2b744a04ae4b"
    }
  }
]